Report

U.S. Pen Needles Market Size, Share, Trends & Forecast 2026-2034

119 pages
U.S. Pen Needles Market Size, Share, Trends & Forecast 2026-2034

U.S. Pen Needles Market Size, Share, Trends & Forecast 2026-2034

U.S. Pen Needles Market Segment: By Product Type (Standard Pen Needles, Safety Pen Needles), By Therapy (Insulin Therapy, GLP-1 Therapy, Other Injectable Therapies), By Needle Length (4 mm, 5 mm, 6 mm, 8 mm, 10–12 mm), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Specialty Pharmacies, Other Channels), By End User (Homecare Settings, Hospitals, Diabetes Clinics, Ambulat... Read more

  • Healthcare
  • Pages : 119
  • Report Delivery Format :  

    pdf ppt xls
  • Author: Pawan Kumar
  • ★ ★ ★ ★ ⯨ (4.5 out of 5)

Note: The market outlook is subject to frequently evolving global trade dynamics and tariff policies. The report will be updated before delivery to incorporate the latest data, including revised forecasts and a detailed analysis of potential impacts to ensure accuracy & up-to-date insights.

U.S. Pen Needles Market Size, Share, Trends & Forecast 2026-2034
Study Period
2021-2034
Market (2026)
USD 0.93 Billion
Market (2034)
USD 2.05 Billion
CAGR
10.40%
Major Markets Players
embecta, Owen Mumford, Ypsomed, Terumo, B. Braun and Others
*Note: Partial List Randomly Ordered

Build Your Custom Market Intelligence Report

Customize Your Report

Key Highlights

  • The U.S. Pen Needles Market was valued at USD 0.93 billion in 2026.
  • The market is forecast to reach USD 2.05 billion by 2034.
  • The market is expanding at a CAGR of 10.40% during 2026-2034.
  • By product type, Standard Pen Needles led with approx 85% share in 2026, while Safety Pen Needles are the faster-growing category.
  • By therapy, Insulin Therapy remains the largest demand area, with an approx 82% share in 2026.
  • Recurring insulin administration across a large diabetes population is the primary growth driver.
  • The competitive landscape is consolidating. In May 2026, embecta announced a deal to acquire Owen Mumford.

Market Outlook

Pen needles are sterile, single-use needles fitted to injection pens for subcutaneous medication delivery, mainly insulin. They are replaced after each injection, so every patient on pen therapy generates recurring demand. The U.S. Pen Needles Market therefore ties closely to diabetes care, clinical injection guidance and access to reimbursed medical supplies.

Demand comes from homecare users, hospitals, diabetes clinics and ambulatory care centers, with retail, hospital, online and specialty pharmacies as the main channels. Needle length, gauge and safety design shape purchasing. Homecare accounts for approx 75% of demand in 2026, reflecting self-administered treatment.

The U.S. Pen Needles Market is projected to grow from USD 0.93 billion in 2026 to USD 2.05 billion by 2034 at a CAGR of 10.40%. Growth is supported by diabetes prevalence, recurring needle replacement, shorter and finer needle designs and wider use of injectable therapies delivered through compatible pens.

The competitive environment includes established diabetes-care manufacturers and specialist device suppliers. Opportunities lie in safety designs, 4 mm needles, online replenishment and pharmaceutical co-packaging. Growth in injectable medicines will not automatically convert into detachable pen needle demand, because some therapies use prefilled or integrated devices.

Government Regulations

Pen needles are regulated as medical devices by the U.S. Food and Drug Administration. The FDA classifies hypodermic single-lumen needles under 21 CFR 880.5570 (product code FMI) as Class II devices, generally requiring 510(k) premarket notification. Manufacturers must also meet Quality Management System requirements covering sterility, design controls, labeling and complaint handling. Workplace sharps rules add a second layer: OSHA’s Bloodborne Pathogens Standard, updated under the Needlestick Safety and Prevention Act, requires employers to evaluate and use safer needle devices, which supports institutional demand for safety pen needles. The CDC’s National Diabetes Statistics Report provides the public-health baseline for the treated population. Together, these frameworks raise entry barriers, favor suppliers with documented quality systems and regulatory clearance, and influence product design and institutional purchasing.

U.S. Pen Needles Market Dynamics

Demand is shaped by the diabetes patient base, recurring insulin administration, clinical guidance on injection technique, reimbursement conditions and the spread of alternative delivery formats. These forces determine both the volume of needles consumed and the mix between standard, safety and shorter-length products.

Factor

Type

Specific Impact on Market

Magnitude

Diabetes prevalence and insulin pen use

Driver

Large treated population creates recurring needle replacement demand

High

Preference for convenient injection systems

Driver

Pen portability and finer, shorter needles support adherence and repeat purchasing

Medium-High

Safety pen needle development

Opportunity

Needlestick protection supports differentiation in institutional settings

Medium

Online and direct-to-consumer supply

Opportunity

Subscription replenishment and home delivery improve convenience

Medium

Reimbursement and pricing pressure

Challenge

Out-of-pocket costs and margin compression affect standard needles

Medium-High

Prefilled and integrated delivery formats

Challenge

Limits conversion of injectable therapy growth into detachable needle demand

Medium-High

Growth Drivers: Rising Diabetes Prevalence and Continued Insulin Use

The CDC’s National Diabetes Statistics Report estimates that 40.1 million people in the United States had diagnosed or undiagnosed diabetes in 2023, including 29.1 million with diagnosed diabetes. Not every patient uses insulin pens, but those who do require a fresh compatible needle for each injection. Because treatment may involve several daily doses, the insulin-treated population creates steady, recurring consumption that underpins the U.S. Pen Needles Market.

Market Opportunities: Safety Pen Needles and Online Distribution

Safety pen needles let manufacturers differentiate through shielding mechanisms that reduce accidental needlestick exposure after injection. Demand is most relevant where healthcare workers, caregivers or patients handle used needles, and OSHA sharps requirements reinforce institutional interest. Online and specialty channels offer a related opportunity, since recurring purchases suit subscription replenishment and home delivery. Adoption will depend on price, usability, prescription rules and insurance coverage, so suppliers with reliable fulfilment and clear compatibility information are better placed.

Industry Challenges: Reimbursement Limits and Alternative Delivery Formats

Pen needles are repeat-purchase supplies, so coverage differences, out-of-pocket costs and price competition directly affect patient purchasing and supplier margins. A second challenge is delivery format. Some injectable medicines, including certain GLP-1 products, are supplied in prefilled pens or autoinjectors that do not need a separately purchased detachable needle. Manufacturers must therefore assess demand at product level rather than assuming total injectable drug growth translates into pen needle sales.


Need Specific Data, Let’s Customize the Report for You

Request Customization

Market Trends: Shift Toward Shorter and Safer Needle Designs

Shorter needles, particularly 4 mm, are gaining clinical attention because they reduce the risk of unintended intramuscular insulin delivery, and the American Diabetes Association’s 2026 Standards of Care support 4 mm pen needles across ages and body types. Manufacturers are also pursuing finer gauges for comfort and safety mechanisms for institutional use. Together, these shifts move the product mix toward premium designs and support the faster modelled growth of safety and 4 mm categories.

U.S. Pen Needles Market Segment Analysis

The U.S. Pen Needles Market is segmented by product type, therapy, needle length, distribution channel, end user and application. Each category reflects a different demand dimension, from device design and clinical use to purchasing channel and care setting.

By End User

  • Homecare Settings
  • Hospitals
  • Diabetes Clinics
  • Ambulatory Care Centers
  • Other Settings

Homecare Settings lead the category with an approx 75% share in 2026, since most patients self-administer insulin and other injectables and buy needles repeatedly through pharmacies or online suppliers. Hospitals are the second analyzed segment, driven by supervised administration, patient education and demand for safety devices to protect staff. Diabetes Clinics, Ambulatory Care Centers and Other Settings contribute smaller volumes through clinical administration and training.

U.S. Pen Needles Market Segment Analysis

By Application

  • Diabetes Management
  • Obesity Management
  • Hormone Deficiency Treatment
  • Other Applications

Diabetes Management leads the category with an approx 82% share in 2026, reflecting the established reliance on insulin pens and the size of the treated population. Obesity Management is the second analyzed segment and is expected to grow quickly as injectable weight-management therapies spread. The addressable need for detachable needles depends on each medicine’s delivery format. Hormone Deficiency Treatment and Other Applications contribute smaller, steadier volumes.

U.S. Pen Needles Market Regional Analysis

The U.S. Pen Needles Market is analyzed across four U.S. regions. Demand varies with diabetes prevalence, insurance coverage, pharmacy networks and the concentration of hospitals and diabetes-care providers. Comparable regional revenue data are not available from the research used, so no regional shares are assigned.

Region

Key Growth Factors

Industry Trends

Northeast

Established hospital networks and specialist diabetes-care access

Institutional demand for safety and shorter needle formats

Midwest

Chronic disease management needs and community providers

Strong retail pharmacy-based supply

South

Large population base and diabetes-care requirements

Homecare-driven recurring demand

West

Healthcare innovation and digital pharmacy services

Growing online and subscription replenishment

Competitive Landscape

The U.S. Pen Needles Market includes established diabetes-care manufacturers and specialist device suppliers. Competition rests on product quality, compatibility with commonly used pens, safety features, distribution partnerships and pricing. The table summarizes participants by general capability and does not represent a market-share ranking.

Company

Competitive Strength

Primary Segment Served

embecta

Ultra-Fine pen needle portfolio with broad U.S. diabetes-care presence

Standard and safety pen needles, insulin therapy

Owen Mumford

Unifine pen needles with comfort and safety-oriented designs

Standard and safety pen needles

Ypsomed

Injection systems and Clickfine pen needles

Insulin and other injectable therapies

Terumo

Broad injection and healthcare product portfolio

Pen needles and injection products

B. Braun

Medical devices and healthcare supplies, category participation requires product-level verification

Hospital and clinical supplies

HTL-STREFA

Single-use medical devices, including needles and injection products

Pen needles and injection-related devices

MHC Medical Products

EasyTouch diabetes-care range

Retail and homecare diabetes supplies

Artsana

InsuPen range and injection-related healthcare products

Insulin pen needles

  • embecta: embecta is a diabetes-care company based in Parsippany, New Jersey, spun off from Becton, Dickinson and Company in 2022, with BD-branded pen needles and insulin syringes now part of its portfolio. Its products are sold in more than 100 countries. It is expanding into pharmaceutical co-packaging of pen needles with generic GLP-1 therapies and is developing market-appropriate pen needles under FDA review. Its competitive strength lies in scale, brand recognition and distribution.
  • Owen Mumford: Owen Mumford is a UK-based medical device company known for the Unifine pen needle range and wider injection and autoinjector technologies for pharmaceutical partners. Its portfolio overlaps with embecta in pen needles, safety pen needles and syringes but extends more broadly into drug-delivery devices. In May 2026, embecta announced an agreement to acquire the company. Its strength lies in comfort-focused needle design, safety products and combination-device development.

Recent Developments and Updates

  • August 2026: embecta’s third-quarter fiscal 2026 results reported that its market-appropriate pen needles are progressing through regulatory review with the U.S. FDA. The company also reported generic GLP-1 therapies featuring embecta pen needles launched in Canada, Brazil and South Africa, showing pharmaceutical co-packaging gaining traction.
  • May 2026: embecta announced an agreement to acquire Owen Mumford, with the deal announced on May 15, 2026. Trade reports put the value at roughly USD 200 million. The deal combines two pen needle portfolios and adds drug-delivery capabilities, signaling consolidation among established suppliers.
  • 2026: FDA records show continued 510(k) activity for pen needle devices under product code FMI and 21 CFR 880.5570, indicating ongoing regulatory submissions and product refresh across the category.

U.S. Pen Needles Market Future Outlook

The U.S. Pen Needles Market is expected to grow steadily through 2034, supported by recurring insulin administration, disposable needle replacement and demand for convenient injection products. Standard pen needles are likely to remain the largest category, while shorter 4 mm needles, finer gauges and safety mechanisms provide differentiation. Online replenishment and pharmaceutical co-packaging offer additional routes to volume, particularly where compatible detachable needles are bundled with injectable therapies.

Competition is likely to center on portfolio breadth, quality systems, distribution reach and pricing, with consolidation such as the embecta and Owen Mumford transaction reshaping positioning. Risks include reimbursement pressure, the shift toward prefilled and integrated delivery devices, and insulin pump adoption reducing demand for traditional pen needles. Manufacturers will need to assess product-level device formats instead of relying on total injectable drug growth.

U.S. Pen Needles Market Report Coverage

This U.S. Pen Needles Market report summarizes market valuation, forecast, segmentation, regional framework and competitive ecosystem for 2026-2034.

Parameter

Details

Market Name

U.S. Pen Needles Market

Market Size (Base Year)

USD 0.93 billion (2026)

Market Size (Forecast Year)

USD 2.05 billion (2034)

CAGR

10.40%

Base Year

2026

Historical Period

2021-2025

Forecast Period

2026-2034

Geographic Scope

United States

Segmentation

By Product Type, By Therapy, By Needle Length, By Distribution Channel, By End User, By Application

Regions Covered

Northeast, Midwest, South, West

Key Companies

embecta, Owen Mumford, Ypsomed, Terumo, B. Braun, HTL-STREFA, MHC Medical Products, Artsana

Customization

Available as per requirement

Why Choose This U.S. Pen Needles Market Report?

  • Presents the 2026 market size, 2034 forecast and 10.40% CAGR for the U.S. Pen Needles Market.
  • Segments the market by product type, therapy, needle length, channel, end user and application.
  • Reviews drivers, opportunities, challenges and trends shaping pen needle demand.
  • Provides regional context across the Northeast, Midwest, South and West, with unavailable shares identified.
  • Profiles key manufacturers by capability and primary segment served.
  • Covers safety needles, shorter needle formats, online channels and GLP-1 co-packaging.
  • Summarizes FDA, CDC and OSHA context to support product, sourcing and investment decisions.

Table of Contents

  1. Introduction
    1. Objective of the Study
    2. Product Definition
    3. Market Segmentation
    4. Study Variables
  2. Research Methodology
    1. Secondary Data Points
      1. Companies Interviewed
    2. Primary Data Points
      1. Breakdown of Primary Interviews
  3. Executive Summary
  4. Market Dynamics
    1. Drivers
    2. Challenges
    3. Opportunity Assessment
  5. Recent Trends and Developments
  6. Policy and Regulatory Landscape
  7. U.S. Electric Water Heater Market Overview and Forecast Analysis (2021-2034)
    1. Market Size, By Value, By Growth Rate (CAGR/USD Billions)
    2. Demand – Supply Trends
    3. Market Share, By Product Type
      1. Storage
      2. Non-Storage
    4. Market Share, By Technology
      1. Electric Resistance Storage
      2. Heat Pump Storage
      3. Instantaneous / Tankless Electric
    5. Market Share, By Capacity
      1. Below 30 Gallons
      2. 30–50 Gallons
      3. 51–80 Gallons
      4. Above 80 Gallons
    6. Market Share, By Application
      1. Residential
      2. Commercial
    7. Market Share, By Distribution Channel
      1. Wholesale
      2. Retail
      3. Online
      4. Direct Sales
    8. Market Share, By End User
      1. Households
      2. Hotels
      3. Hospitals
      4. Restaurants
      5. Educational Institutions
      6. Offices
      7. Industrial & Other Commercial
    9. Market Share, By Region
      1. Northeast
      2. Midwest
      3. South
      4. West
    10. Market Share, By Competitors
      1. Competition Characteristics
      2. Revenue Shares
  8. Storage U.S. Electric Water Heater Market Overview, 2021-2034F
    1. By Value (USD Million)
    2. By Technology – Market Size & Forecast 2021-2034, USD Million
      1. Electric Resistance Storage
      2. Heat Pump Storage
      3. Instantaneous / Tankless Electric
  9. Non-Storage U.S. Electric Water Heater Market Overview, 2021-2034F
    1. By Value (USD Million)
    2. By Technology – Market Size & Forecast 2021-2034, USD Million
      1. Electric Resistance Storage
      2. Heat Pump Storage
      3. Instantaneous / Tankless Electric
  10. Competitive Outlook (Company Profile – Partial List)
    1. A.O. Smith Corporation
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    2. Rheem Manufacturing Company
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    3. Bradford White Corporation
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    4. GE Appliances
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    5. Bosch Thermotechnology
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    6. Stiebel Eltron
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    7. Rinnai America Corporation
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    8. Hubbell Electric Heater Company
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    9. Midea Group
      1. Company Overview
      2. Business Segments
      3. Strategic Alliances/Partnerships
      4. Recent Developments
    10. Others
  11. Contact Us & Disclaimer

Top Key Players & Market Share Outlook

  • embecta
  • Owen Mumford
  • Ypsomed
  • Terumo
  • B. Braun
  • HTL-STREFA
  • MHC Medical Products
  • Artsana

Frequently Asked Questions

A. The U.S. Pen Needles Market is valued at USD 0.93 billion in 2026. For further details on this market, request a sample here.

A. The U.S. Pen Needles Market is forecast to reach USD 2.05 billion by 2034. For further details on this market, request a sample here.

A. The U.S. Pen Needles Market is projected to grow at a CAGR of 10.40% during 2026-2034. For further details on this market, request a sample here.

A. Standard Pen Needles lead by product type with an approx 85% share in 2026. Insulin Therapy leads by therapy with an approx 82% share. For further details on this market, request a sample here.

A. Regional shares for the Northeast, Midwest, South and West were not supplied or verified, so no dominant region is identified. For further details on this market, request a sample here.

A. Who are the key companies in the U.S. Pen Needles Market? For further details on this market, request a sample here.

Few of Our Trusted Clients

  • 3M
  • GE
  • PandG
  • Siemens
  • ONGC
  • Honeywell